Human Leukocyte Antigen Matching Estimations in a Hypothetical Bank of Human Embryonic Stem Cell Lines in the Japanese Population for Use in Cell Transplantation Therapy
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Human embryonic stem (hES) cell lines are of great potential in cell transplantation therapy. However, recipients of such allogeneic transplants probably need treatment with immunosuppressants. Recently, Taylor et al. [Lancet 2005;366:2019-2025] proposed banking of hES cell lines and estimated the required number of hES cell lines for beneficial human leukocyte antigen (HLA) matching in the U.K. population. Here, we carried out such an estimation in the Japanese population. We calculated the proportion of patients who can find at least one HLA-matched donor at three loci of HLA-A, -B, and -DR. With a bank of hES cell lines from 170 randomly selected donated embryos, 80% of patients were expected to find at least one hES cell line with a single mismatch at one HLA locus or a better match. Furthermore, 80% of patients are expected to find at least one donor with complete matching at the three HLA loci if parthenogenetic homozygous hES cell lines are established from 55 randomly selected donated oocytes. The relatively low ethnic diversity of the Japanese population may have resulted in a high success rate in beneficial matching. Moreover, parthenogenetic hES cell lines can greatly reduce the number required for a higher degree of HLA matching.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, an HLA iPSC bank with iPSCs derived from 55 donors can be used to perform iPSC-based cell therapy for 80% of the Japanese population, a country with limited HLA variability [106].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [106]
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Embryonic Stem Cell Lines Derived from Human Blastocysts
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., & Jones, J. M. (1998) · Science · doi:10.1126/science.282.5391.1145 · Cited by 15,926
Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro
Reubinoff, B. E., Pera, M. F., Fong, C.-Y., Trounson, A., & Bongso, A. (2000) · Nature Biotechnology · doi:10.1038/74447 · Cited by 2,706
Taylor, C. J., Bolton, E. M., Pocock, S., Sharples, L. D., Pedersen, R. A., & Bradley, J. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67813-0 · Cited by 493
Petersdorf, E. W., Gooley, T. A., Anasetti, C., Martin, P. J., Smith, A. G., Mickelson, E. M., Woolfrey, A. E., & Hansen, J. A. (1998) · Blood · doi:10.1182/blood.v92.10.3515 · Cited by 480
Drukker, M., Katchman, H., Katz, G., Even-Tov Friedman, S., Shezen, E., Hornstein, E., Mandelboim, O., Reisner, Y., & Benvenisty, N. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0188 · Cited by 402
Parthenogenetic Stem Cells in Nonhuman Primates
Cibelli, J. B., Grant, K. A., Chapman, K. B., Cunniff, K., Worst, T., Green, H. L., Walker, S. J., Gutin, P. H., Vilner, L., Tabar, V., et al. (2002) · Science · doi:10.1126/science.1065637 · Cited by 311
Suemori, H., Yasuchika, K., Hasegawa, K., Fujioka, T., Tsuneyoshi, N., & Nakatsuji, N. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.04.135 · Cited by 300
HLA Typing and Its Influence on Organ Transplantation
Sheldon, S., & Poulton, K. (2006) · Humana Press eBooks · doi:10.1385/1-59745-049-9:157 · Cited by 130
Navarro, V. J., Herrine, S. K., Katopes, C., Colombe, B., & Spain, V. C. (2006) · Liver Transplantation · doi:10.1002/lt.20680 · Cited by 96
Research works printed but not linked: 1
- Imanishi, 1992, HLA 1991, 76
Cited by
Items 101–168 of 168
iPSC for Dental Tissue Regeneration
Hynes, K., Gronthos, S., & Bartold, P. M. (2014) · Current Oral Health Reports · doi:10.1007/s40496-013-0001-8 · Cited by 10
Varrault, A., Eckardt, S., Girard, B. J. T., Digarcher, A. L., Sassetti, I., Meusnier, C., Ripoll, C., Badalyan, A., Bertaso, F., McLaughlin, K. J., et al. (2017) · Stem Cells · doi:10.1002/stem.2721 · Cited by 10
iPSC-Derived Corneal Endothelial Cells
Zhou, Q., Li, Z., & Duan, H. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_644 · Cited by 9
Retinal transplant immunology and advancements
Perez, V. L., Mousa, H. M., Miyagishima, K. J., Reed, A. A., Su, A.-J. A., Greenwell, T. N., & Washington, K. M. (2024) · Stem Cell Reports · doi:10.1016/j.stemcr.2024.04.007 · Cited by 10
Generation of Induced Pluripotent Stem Cells from Dental Pulp Somatic Cells
Nelson, F., Kerkis, I., & Wenceslau, C. V. (2013) · InTech eBooks · doi:10.5772/55856 · Cited by 9
“…homozygous alleles of the 3 HLA loci (A, B, and DR), would cover ~ Generation of Induced Pluripotent Stem Cells from Dental Pulp Somatic Cells http://dx.doi.org/10.5772/55856 141 90% of the Japanese population with a faultless match of these loci (Nakajima et al., 2007; Nakatsuji et al., 2008).”
BackgroundInfluentialScalable Manufacture for Cell Therapy Needs
Rafiq, Q., Heathman, T., Coopman, K., Nienow, A., & Hewitt, C. (2016) · Wiley eBooks · doi:10.1002/9783527683369.ch4 · Cited by 7
Retinal cell transplantation in retinitis pigmentosa
Tezel, T. H., & Ruff, A. (2021) · Taiwan Journal of Ophthalmology · doi:10.4103/tjo.tjo_48_21 · Cited by 11
“[107] This challenge will be enormous in countries with diverse ethnic backgrounds, such as Brazil,[108] compared to ethnically more homogenous countries such as Japan[109,110] and the United Kingdom.”
BackgroundHuman Embryonic Stem Cells in Regenerative Medicine
Yabut, O., & Bernstein, H. S. (2011) · Humana Press eBooks · doi:10.1007/978-1-61779-322-6_2 · Cited by 7
Gene therapy by allele selection in a mouse model of beta-thalassemia
Eckardt, S., Leu, N. A., Yanchik, A., Hatada, S., Kyba, M., & McLaughlin, K. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45377 · Cited by 7
“If they are MHC-homozygous, such PG ES cell lines could be immune compatible with the patient’s offspring, and potentially with a wider proportion of the population (31).”
BackgroundBehl, T., Kaur, I., Sehgal, A., Singh, S., Sharma, N., Chigurupati, S., Felemban, S. G., Alsubaiyel, A. M., Iqbal, M. S., Bhatia, S., et al. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10390-4 · Cited by 6
Challenges of cell therapies for retinal diseases
Monville, C., Morizur, L., & M’Barek, K. B. (2022) · International review of neurobiology · doi:10.1016/bs.irn.2022.09.004 · Cited by 6
Gaskell, T. L., Englund, M. C. O., & Hyllner, J. (2016) · Springer eBooks · doi:10.1007/978-3-319-27610-6_2 · Cited by 9
“However, studies of renal allograft donor-recipient relations give fuel for speculation that a relatively low number of hES cell lines, in the range of low hundreds or ever less, would cover the larger proportion of the population for future therapies (Nakajima et al. 2007; Taylor et al. 2005), and as discussed by Dal…”
BackgroundSun, B., Yu, W., Wang, F., Song, W., Jin, H., & Sun, Y. (2014) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-014-0308-y · Cited by 6
“Since the heterogeneous behavior of the distinct lines of hESC regarding their differentiation potential [24] and their epigenetic stability [25], it is very important to establish hESCs from multiple sources [26, 27].”
BackgroundUse of Human Embryonic Stem Cells in Therapy
Fraga, A. M., de Araújo, É. S. S., Vergani, N., Fonseca, S. A. S., & Pereira, L. V. (2013) · Cell engineering · doi:10.1007/978-94-007-7196-3_1 · Cited by 5
Ishihara, K., Ichinomiya, A., Inami, M., Hashimoto, T., Yuzawa, R., Ishizu, M., Hirohara, T., Yashiro, Y., & Takizawa, T. (2016) · Regenerative Therapy · doi:10.1016/j.reth.2016.09.003 · Cited by 5
“For transplantation of an organ or tissue, it is necessary to at least partially match the human leukocyte antigen (HLA) between the donor and recipient to reduce the incidence of graft rejection; three loci, HLA-A, -B, and DR, are important for this process [27,28].”
BackgroundUniversal and hypoimmunogenic pluripotent stem cells for clinical usage
Sung, T., Maitiruze, K., Pan, J., Gong, J., Bai, Y., Pan, X., & Higuchi, A. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.02.014 · Cited by 6
Ji, T., Niu, S., Fang, M., Xu, L., Wang, X., Zou, J., Xu, F., Zhang, M., Niu, R., Wu, J., et al. (2023) · Cell Proliferation · doi:10.1111/cpr.13471 · Cited by 5
Induced Pluripotent Stem Cells
Okita, K., & Yamanaka, S. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-385942-6.00018-4 · Cited by 6
Cell Therapy Using Embryonic Stem Cell Source in Clinical Trial Studies: Advantages and Limitations
Golchin, A., & Niknejad, H. (2017) · Majallah-i dānishgāh-i ̒ulūm-i pizishkī-i Māzandarān/Journal of Mazandaran University of Medical Sciences · Cited by 4
Englund, M. C. O., Sartipy, P., & Hyllner, J. (2010) · Springer eBooks · doi:10.1007/978-90-481-9075-1_7 · Cited by 5
Yabuuchi, A., Rehman, H., & Kim, K. (2012) · Journal of Mammalian Ova Research · doi:10.1274/jmor.29.17 · Cited by 4
“[22], if parthenogenetic human ES cell lines are established from 55 randomly selected oocyte donors, 80% of patients are expected to find at least one donor with complete matching at all three HLA loci in the Japanese population.”
Biobanks for Pluripotent Stem Cells
Luong, M. X., Smith, K. P., Crook, J. M., & Stacey, G. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-385473-5.00008-4 · Cited by 3
Pateraki, P., Latsoudis, H., Παπαδοπούλου, Α., Gontika, I., Fragiadaki, I., Mavroudi, I., Bizymi, N., Batsali, A. K., Klontzas, M. E., Xagorari, A., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13041152 · Cited by 3
“…the qualitative properties of PL obtained from small volume, non-suitable for HSCT UCB units, in terms of growth factor A number of clinical studies have been performed using allogeneic UCB PRP derivatives and have shown their beneficial effect in a variety of conditions such as…”
BackgroundEmbryonic Stem Cells for Therapies – Challenges and Possibilities
Yeo, R. W. Y., & Lim, S. K. (2011) · InTech eBooks · doi:10.5772/23762 · Cited by 4
“One proposed strategy was to establish ESC repositories with lines expressing the combinations of HLA molecules that are compatible with HLA haplotypes present in the population (Nakajima et al., 2007; Taylor et al., 2005).”
MethodImmunological Properties of Murine Parthenogenetic Stem Cells and Their Differentiation Products
Johannsen, H., Muppala, V., Gröschel, C., Monecke, S., Elsner, L., Didié, M., Zimmermann, W., & Dressel, R. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00924 · Cited by 3
“Therefore, allogeneic transplantations of grafts derived from banked HLAmatched pluripotent stem cell lines (4, 28, 29) might be a more feasible alternative (44).”
BackgroundConstruction of Human Embryonic Stem Cell Banks: Prospects for Tissue Matching
Lin, G., Ou-Yang, Q., Qian, X., & Lu, G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5480-9_7 · Cited by 4
Coulombel, L., critique, A. L. R., & Pucéat, M. (2008) · médecine/sciences · doi:10.1051/medsci/2008244419 · Cited by 3
Genome Editing of Pluripotent Stem Cells for Adoptive and Regenerative Cell Therapies
Blassberg, R. A. (2022) · GEN Biotechnology · doi:10.1089/genbio.2021.0010 · Cited by 3
“57 Despite the impressive coverage of patients likely to benefit from feasibly small collections of banked donor iPSCs, coverage through such exercises is likely to remain incomplete.”
Reprogrammed Parthenogenetic ES Cells - New Choice for Regenerative Medicine
Horii, T., & Hat, I. (2011) · InTech eBooks · doi:10.5772/13915 · Cited by 2
“The hES cell bank that contains sufficient cell lines with diverse human leukocyte antigen (HLA) genotypes (Taylor et al., 2005; , Nakajima et al., 2007) might serve most of the patients in a region; however, this system need numerous numbers of human embryos and might cause ethical issues.”
BackgroundAdvantages and limitations of the parthenogenetic embryonic stem cells in cell therapy
Yu, Z., Yu, F., Bao-sheng, & Han (2016) · doi:10.7669/j.issn.1001-7844.2016.02.0118 · Cited by 2
State of the Art in Cardiomyocyte Transplantation
Hartman, M. E., Chong, J. J. H., & Laflamme, M. A. (2017) · Cardiac and vascular biology · doi:10.1007/978-3-319-56106-6_9 · Cited by 2
Stem cell-based therapies for neurological disorders
Tamura, R., & Toda, M. (2018) · AIMS Cell and Tissue Engineering · doi:10.3934/celltissue.2018.1.24 · Cited by 2
“The aim of the stock is to hold iPS cells of guaranteed quality which can be supplied quickly to medical care institutions and research institutions when required [40].”
Induced pluripotent stem cells–derived hematopoietic progenitors for cellular immunotherapies
Slukvin, I. I., D'Souza, S. S., & Kumar, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85545-7.00007-7 · Cited by 2
An update on clinical applications of iPSCs from a genomic point of view
Yoshihara, M., & Murakawa, Y. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99892-5.00001-3 · Cited by 2
Stem Cell and Gene Therapy for Inherited Retinal Diseases
DeSouza, P. J., Park, U. C., & Park, S. S. (2022) · Springer eBooks · doi:10.1007/978-981-16-7337-5_3 · Cited by 2
Induced Pluripotent Stem Cells
Okita, K., & Yamanaka, S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-381422-7.10013-6 · Cited by 2
Induced pluripotent stem cells (iPSCs): Where are we and where are we heading?
Jamal, A. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.11.13 · Cited by 2
“Assumingly, HLA-homozygous and blood group O donors dependent iPSCs biobank would streamline the donor-recipient matching (24).”
BackgroundTherapeutic Cloning and Cellular Reprogramming
Rodríguez, R. M. A., Ross, P. J., & Cibelli, J. B. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-2098-9_18 · Cited by 2
Lee, J. E., Kang, M. S., & Lee, D. R. (2012) · Springer eBooks · doi:10.1007/978-94-007-2993-3_4 · Cited by 1
Nanoengineering of stem cells for musculoskeletal regeneration
Navaei, T., Hasani, S., & Derakhshani, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820262-3.00006-2 · Cited by 1
Englund, M. C. O., Sartipy, P., & Hyllner, J. (2013) · Springer eBooks · doi:10.1007/978-94-007-5690-8_7 · Cited by 1
Generation of Definitive Engraftable Hematopoietic Stem Cells from Human Pluripotent Stem Cells
Daheron, L. M., & Scadden, D. T. (2015) · Wiley eBooks · doi:10.1002/9781118416426.ch3 · Cited by 2
Início e manutenção da inativação do cromossomo X em células humanas
Fraga, A. M. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.41.2012.tde-17072012-090204 · Cited by 4
Innovation and Commercialisation of Induced Pluripotent Stem Cells
Sengoku, S. (2015) · Wiley eBooks · doi:10.1002/9781118846193.ch24 · Cited by 1
Fisher, M. C., Ackley, T., Richard, K. E., Oei, B., & Dealy, C. N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64119-3 · Cited by 5
Induced Pluripotent Stem Cells
Takahashi, K., & Yamanaka, S. (2012) · Wiley-VCH eBooks · doi:10.1002/3527600906.mcb.201100023 · Cited by 1
Myocardial Repair and Restoration
Wong, S. S. Y., & Bernstein, H. S. (2011) · Humana Press eBooks · doi:10.1007/978-1-61779-322-6_9
Nolden, L., & Brüstle, O. (2008) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-008-0631-5
Cervera, R. P., & Stojković, M. (2013) · Wiley eBooks · doi:10.1002/9783527669417.ch2
Pluripotent Stem Cell‐Derived Cardiomyocytes for Industrial and Clinical Applications
Hudson, J. E., Christalla, P., & Zimmermann, W. (2013) · Wiley eBooks · doi:10.1002/9783527669417.ch3
Human cord blood reprogrammed into embryonic‐like stem cells
Giorgetti, A., Fazzina, R., Li, M., & Belmonte, J. C. I. (2011) · ISBT Science Series · doi:10.1111/j.1751-2824.2011.01450.x
international sur la recherche dédiée aux cellules souches embryonnaires humaines
Coulombel, L., Médecine, & Brousse, H. P. (2008)
Immunnogenic aspects of stem cell therapy in regenerative medicine
Mazhari, R., & Toma, I. (2014) · Moldovan Journal of Health Sciences
Galla, S. (2016) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5699
Stem cells and regenerative medicine
Fernandes, T. G., Diogo, M. M., & Cabral, J. M. S. (2013) · Elsevier eBooks · doi:10.1533/9781908818300.177
Biobanks for Induced Pluripotent Stem Cells and Reprogrammed Tissues
Carpenter, L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407785-0.00014-1
Human Embryonic Stem Cell-derived Tissue Transplantation Therapy: Clinical Hurdles
Gauthaman, K., Fong, C., & Bongso, A. (2010) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814289399_0006
Human Embryonic Stem Cells and Tissue Regeneration
Yabut, O., Ritner, C., & Bernstein, H. S. (2012) · CRC Press eBooks · doi:10.1201/b12083-23
Merlini, A., Feo, D. D., Radaelli, M., Laterza, C., Ciceri, F., & Martino, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801914-6.00029-5 · Cited by 1
Johannsen, H. (2017) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-6211
Supply Chain Considerations and Strategies for Regenerative Medicine Products
Rafiq, Q. A., & Harrison, R. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65607-6
Modelling severe paediatric aplastic anaemia using induced pluripotent stem cell technology
Melguizo‐Sanchis, D. (2017)
Nolden, L., & Brüstle, O. (2008) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
Conclusions and Future Perspective on Biomaterial Control of Therapeutic Stem Cells
(2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788012690-00374
Takenaka-Ninagawa, N., Ito, A., & Aoyama, T. (2017) · Orthopaedic Section, APTA, Inc. eBooks · doi:10.17832/isc.2017.27.4.3
Cell therapy and biomanufacturing using hiPSC-derived neurons
Casabona, J. C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822277-5.00009-2
Dopaminergic-Induced Pluripotent Stem Cells for Parkinson’s Disease
Boehringer, A. V., & Kordower, J. H. (2025) · Springer eBooks · doi:10.1007/978-3-031-89307-0_13
Modelling Parkinson's disease with patient induced pluripotent stem cells
Thamrin, N. P. (2022) · theses.fr (ABES) · doi:10.70675/2021f43cz12b4z4d3eza533zba4392d2ad4d
Metadata
- Authors
- Nakajima, F., Tokunaga, K., & Nakatsuji, N.
- Affiliations
- Japanese Red Cross Society, Japan (JP)
- The University of Tokyo (JP)
- Kyoto University (JP)
- Corresponding author
- Tokunaga, Katsushi
- Nakatsuji, Norio
- Venue
- Stem Cells
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-12-21
- Volume
- 25
- Issue
- 4
- Pages
- 983-985
- ISSN
- 1066-5099 (ISSN-L)
- 1549-4918
- OpenAlex
- W2093267077
- Cited by
- 168
- References
- 15
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 4 · 2022: 11 · 2021: 4 · 2020: 6 · 2019: 7 · 2018: 9 · 2017: 9 · 2016: 13 · 2015: 14 · 2014: 12 · 2013: 10 · 2012: 19
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Stem Cells (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Education, Science and Technology
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Keywords
- human embryonic stem cell lines, HLA matching, HLA typing, stem cell banking, allogeneic cell transplantation, immunosuppression, HLA-A, HLA-B, HLA-DR, parthenogenetic embryos, Japanese population, ethnic diversity, donor availability
- MeSH terms
- Cell Line, Family, Female, Histocompatibility Testing, HLA Antigens, Humans, Japan, Male, Parthenogenesis, Tissue Banks, Stem Cell Transplantation, Cord Blood Stem Cell Transplantation, Embryonic Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.